Indications
Therapeutic Asset Ratings
6,305 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Silmitasertib
Liposarcoma
Milton S. Hershey Medical Center
P1/2
CC
(47)
Sirolimus
Frontotemporal Dementia
Prevail Therapeutics
P1/2
CC
(47)
Sirolimus
Skin Basal Cell Carcinoma
National Cancer Institute (NCI)
P1/2
CC
(47)
SL-28
Head And Neck Cancer
Second Life Therapeutics
P1/2
CC
(47)
SL-28
Malignant Pancreatic Neoplasm
Second Life Therapeutics
P1/2
CC
(47)
SLC391
Lung Carcinoma
SignalChem Lifesciences Corporation
P1/2
CC
(47)
Solnerstotug
Cervical Cancer
Sensei Biotherapeutics, Inc.
P1/2
CC
(47)
Solnerstotug
Uterine Cancer
Sensei Biotherapeutics, Inc.
P1/2
CC
(47)
Sonrotoclax
B-Cell Neoplasm
BeOne Medicines
P1/2
CC
(47)
Sonrotoclax
Myelodysplastic/Myeloproliferative Neoplasm
BeiGene
P1/2
CC
(47)
Sotorasib
Malignant Pancreatic Neoplasm
Devalingam Mahalingam
P1/2
CC
(47)
st101
Melanoma
Sapience Therapeutics
P1/2
CC
(47)
st-503
Neuropathy, Painful
Sangamo Therapeutics
P1/2
CC
(47)
Star0602
Lung Neoplasm
Marengo Therapeutics, Inc.
P1/2
CC
(47)
Star0602
Neoplasm
Marengo Therapeutics, Inc.
P1/2
CC
(47)
Star0602
Urinary System Neoplasm
Marengo Therapeutics, Inc.
P1/2
CC
(47)
Stc-15
Dedifferentiated Liposarcoma
STORM Therapeutics LTD
P1/2
CC
(47)
Stc-15
Leiomyosarcoma
STORM Therapeutics LTD
P1/2
CC
(47)
Sulfur Hexafluoride
Glioblastoma
University of Cincinnati
P1/2
CC
(47)
Sulfur Hexafluoride
Nervous System Neoplasm
NaviFUS Corporation
P1/2
CC
(47)
Sumarotene
Metastatic Prostate Carcinoma
CuraCell TX AB
P1/2
CC
(47)
Supcd7 Cart Cells
T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P1/2
CC
(47)
Surovatamig
B-Cell Chronic Lymphocytic Leukemia
AstraZeneca
P1/2
CC
(47)
svg103
Tuberous Sclerosis
Sovargen
P1/2
CC
(47)
SX682
Adenoid Cystic Carcinoma
National Cancer Institute (NCI)
P1/2
CC
(47)
Showing 2626 to 2650 of 6,305 assets
Previous
Page 106 of 253
Next